[{"id":"353049ea-1a4c-45b8-a1c4-3e6301267194","acronym":"","url":"https://clinicaltrials.gov/study/NCT05393804","created_at":"2022-05-26T16:55:32.011Z","updated_at":"2025-02-25T13:54:28.487Z","phase":"Phase 2","brief_title":"A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant","source_id_and_acronym":"NCT05393804","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Abecma (idecabtagene vicleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-20"},{"id":"81d99580-964a-4d43-9dfd-629d1f93a58c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642626","created_at":"2021-01-18T17:52:54.288Z","updated_at":"2024-07-02T16:35:14.310Z","phase":"","brief_title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","source_id_and_acronym":"NCT03642626","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/18/2018","start_date":" 12/18/2018","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-03-18"},{"id":"99616051-22a3-4061-a383-daee6d30961a","acronym":"BMTCTN1902","url":"https://clinicaltrials.gov/study/NCT05032820","created_at":"2021-09-02T14:53:04.280Z","updated_at":"2025-02-25T14:16:18.481Z","phase":"Phase 2","brief_title":"MM CAR-T to Upgrade Response BMTCTN1902","source_id_and_acronym":"NCT05032820 - BMTCTN1902","lead_sponsor":"Marcelo Pasquini, MD","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-01-08"}]